BLIS PROBIOTICS was an established local brand in New Zealand when it joined the iNova portfolio in 2018, through a long-term exclusive license and distribution arrangement with BLIS Technologies.
BLIS PROBIOTICS is the world’s first market-approved targeted throat probiotic, discovered by Australian Professor, John Tagg, and further developed and commercialised by BLIS Technologies in New Zealand. BLIS Technologies shares iNova’s core values of innovation, expertise and desire to improve the health and wellbeing of our customers. The ongoing partnership between iNova Pharmaceuticals and BLIS Technologies leverages the strengths and expertise of both parties.
The BLIS PROBIOTICS Australian launch in 2019 – dubbed the most exciting product launch in the probiotic category for the year – was fast tracked by a full year and was executed within 6 months.
Supported by a dedicated iNova team, the launch incorporated a comprehensive marketing program including Australian packaging design, in-store promotion, television commercial, display advertisements, targeted online videos, advertorials and influencer partnerships to drive consumer awareness and trial during the launch period. To build professional awareness and recommendation, iNova also rolled out an education program targeting Pharmacists and Pharmacy Assistants nationally.
With a unique value proposition, success and loyalty in its home market and potential for geographic expansion, BLIS PROBIOTICS is exactly the kind of brand we look to own or distribute at iNova Pharmaceuticals.
Our door is always open to prospective vendors and business partners here at iNova Pharmaceuticals!